Research at OnkPat
OnkPat consists of more than 30 research groups
33 million SEK to OnPat researchers from Radiumhemmets Forskningsfonder
In this year's announcement of project grants from Radiumhemmets Forskningsfonder, OnkPat received a total of 33 million SEK. 32 researchers were granted funding. The largest grant was 3 million SEK received by professor Anders Österborg.
Double embryo transfer in assisted reproduction increased the risk of complications in singleton births
The risk of complications in assisted reproduction is higher when two embryos are transferred, instead of one embryo. This has been shown in a study published by professor Kenny Rodriguez-Wallberg and Frida Lundberg in the journal JAMA Pediatrics, which included all births in Sweden 2007-2017.
Identification of breast cancer patients with poor survival who may benefit from alternative treatment
Alexios Matikas, Theodoros Foukakis and colleagues have published an article from the Swedish randomized trial PREDIX HER2 in Clinical Cancer Research. They show that early response to preoperative treatment according to PET/CT predicts long-term survival. In addition, combined assessment of on-treatment PET/CT and baseline tumor infiltrating lymphocytes (TILs) counted by using machine learning-based image analysis identifies patients with poor response to treatment and worse survival. These results suggest that early identification of poor responders by using PET/CT and digital TILs may facilitate adaptation of the preoperative strategy.
Potential new treatment for tumors with nonsense mutant TP53
Mireia Palomar-Siles, Angelos Heldin and Klas Wiman with colleagues have published an article in Cell Death & Disease which shows that 5-Fluorouridine can induce full-length funtional p53 protein in cancer cells with nonsense mutation in TP53, the gene encoding p53. The induction of full-length p53 triggers cancer cell death. These results suggest that 5-Fluorouridine should be explored as potential therapeutic agent for tumors with nonsense mutant TP53.